Who We Are
An AI-native biotechnology company centered on AI Virtual Cells
Beijing Infinite Evolution Technology Co., Ltd. (INFevo) is an AI-native biotechnology company incubated by XtalPi (2228.HK) in Beijing. INFevo builds AI Virtual Cell (AIVC) foundation models and automated experimental loops to predict cellular responses to genetic, chemical, and environmental perturbations, supporting disease-mechanism research, target discovery, and drug screening.
Through our OCOO models and automated cell experimentation platform, we connect computational prediction, in-vitro validation, and model iteration. Each experiment tests a hypothesis and contributes data to the next learning cycle.
On this foundation, we are developing a traceable, evaluable, and continuously improving system for autonomous scientific discovery, so important biological questions can be proposed, tested, and advanced more systematically.
In June 2026, INFevo announced an angel financing round of tens of millions of RMB with participation from Shunwei Capital, HongShan, and Songhe Capital. In August 2026, the company joined work around the Beijing Key Laboratory for hepatobiliary-pancreatic tumor organoids and intelligent diagnosis.
Public sources and papers: OCOO-T preprint · Company update
Our Approach
Three layers from modeling to validation
Multimodal Foundation AI Model
A generative foundation model trained on large-scale multi-omic data to learn biological patterns across species and states, turning complex systems into representations that can be analyzed and predicted.
Dynamic Evolving Knowledge Graph
A multidimensional knowledge system connecting molecules, pathways, phenotypes, and clinical outcomes. It does not simply store existing knowledge; it evolves with every experiment.
In-Silico to In-Vitro Closed Loop
A direct link between computational prediction and automated in-vitro validation. We do not only predict biology; we test it experimentally and feed the results back into the model.
Technology & Research
Clear technical scope, published evidence, and application boundaries
We explain the core capabilities we are building and provide primary links for research progress that can be independently reviewed.
See the unseen, heal the untreated.
INFevo · Core Vision
The Team
A cross-disciplinary team spanning research, engineering, and industry
Our team works at the intersection of biology, artificial intelligence, mathematics, and drug discovery, combining frontier research with experience bringing technology into real R&D settings.
- MIT
- Tsinghua University
- Peking University
- University of Chicago
- Carnegie Mellon University
- Zhejiang University
- Broad Institute
- Harvard Medical School
- Sanofi
- Arc Institute
- XtalPi
- Microsoft Research
- Alibaba
- IBM Research
Understanding life is where better medicine begins.
We welcome conversations with investors, research institutions, and industry partners who share a long-term commitment to turning deeper biological understanding into meaningful medical progress.